Peptide therapy inquiries shifted dramatically after the 2023 FDA bulk import restrictions. Patients who used to buy research-grade BPC-157 online now need a legitimate prescribing physician and a 503A compounding pharmacy. They arrive at your clinic confused: is BPC-157 still prescribable, what does semaglutide actually cost, is sermorelin the same as HGH, and how does a cycle work. The medical staff fields the same education questions all day while trying to manage actual treatment.

SleekAI maps your peptide protocols by goal (injury recovery: BPC-157, TB-500; metabolic: semaglutide, tirzepatide; growth hormone axis: sermorelin, CJC-1295, ipamorelin; cognitive: selank, semax), your prescriber bios with MD and NP credentials, your partner compounding pharmacy details, dose schedules per peptide, and pricing tiers. When a patient asks about BPC-157 for a partial Achilles tear, the bot quotes the typical 4-6 week subcutaneous protocol, the dose (250mcg twice daily), the pharmacy partner that compounds it, and the $349 starting cost for the cycle.

Generic chatbots either treat peptides like dietary supplements or refuse to discuss them at all. SleekAI lets your clinic answer with the current legal and clinical reality. Some peptides are still routinely prescribable through 503A pharmacies. Others are restricted or have been moved to 503B status. The bot reads your specific protocols, your current pharmacy partners, and your prescriber's scope, and gives patients an honest answer instead of marketing language that gets contradicted at the consult.

Peptide therapy patients live in a regulatory fog. They read posts from 2021 that promised research-grade BPC-157 from any online source, then learned in 2023 that the FDA restricted bulk imports, and now they don't know what's actually legal to prescribe. They arrive at your clinic with bad information, expect prices that don't reflect the compounding pharmacy reality, and are skeptical when a real prescribing process takes 4-6 weeks from consult to first injection.

SleekAI lets your clinic clear the fog quickly. The bot reads your current protocols, your active pharmacy partners, and your licensure map, and gives patients an accurate picture of what's prescribable, at what cost, on what timeline. BPC-157 is still available through 503A compounding for specific indications.

Real HGH is not prescribed outside FDA-approved deficiency. Compounded semaglutide is real, monitored, and meaningfully cheaper than retail brand-name for uninsured patients. The honesty distinguishes your clinic from the gray-market suppliers patients are comparing you to.

Generic chatbots either treat peptides as supplements or refuse to discuss them. SleekAI lets your prescribers set the exact framing. The bot quotes your dose protocols, your consult pricing, your pharmacy partners, and your state licensure.

The clinical boundary stays intact because dose adjustments, prescription decisions, and contraindication clearance all happen at the consult. The bot accelerates the education without crossing into prescribing. Patients arrive informed, the consult is more productive, and the prescriber spends time on the clinical conversation instead of repeating the same 503A explanation forty times a week.

The compounding effect over months is a more efficient clinic with patients who trust the process because their first chat answered the questions accurately.